Skip to content
GradedGrading live · 2026
LongevityGraded
Menu

Graded review

Concierge vs Membership Longevity: What You Actually Get

Concierge clinics ($8k–$25k/yr) sell diagnostics; membership programs ($99–$300/mo) sell ongoing treatment. What each delivers, and where the money goes.

Researched & graded by Tom Vance · Lead Reviews Analyst
Last graded
Evidence scorecard

Two providers both call themselves "longevity medicine." One charges $19,000 a year, scans your whole body in an MRI tube, sequences your genome, and assigns you a concierge physician. The other charges $149 a month, mails you a lab kit, and prescribes peptides or hormones over a video call. The price gap is roughly tenfold — and most of what you're actually buying is different in kind, not degree.

This is the comparison that matters most once you've decided you want hands-on longevity care rather than a DTC lab that tests but doesn't treat. The honest framing: a concierge clinic sells you diagnostics; a membership program sells you ongoing treatment. Both can be worth it. Neither has been shown to extend human lifespan. Here is what your money actually buys in each model, and how to decide.

The two models side by side

| | Concierge diagnostic clinic | Membership longevity program | |---|---|---| | Price (2026) | $8,000–$25,000/yr | $99–$300/mo (~$1,200–$3,600/yr) | | Examples | Fountain Life, Human Longevity, Cenegenics | Lifeforce, Next Health, Healthspan, CoreAge Rx | | Core product | Imaging + genomics + MD concierge | Recurring labs + clinician + prescribed therapies | | Delivery | In-person, high-touch | Telehealth + mailed lab kits (mostly) | | What it's best at | Deep one-time diagnostic picture | Longitudinal treatment + retesting | | The honest catch | Over-screening risk; bolt-on unproven therapies | "Healthspan" framing; supplement/vertical-pharmacy upsells |

The single distinction to carry through everything below: does the price buy you a picture, or a plan? Concierge buys the picture — the most detailed scan of your body a consumer can get. Membership buys the plan — a clinician who prescribes, a retesting cadence, and someone watching the numbers over time. The mistake people make is paying concierge prices expecting a plan, or membership prices expecting concierge-grade imaging.

Model Comparison

Concierge clinicMembership program
Price (2026)$8,000–$25,000/yr$99–$300/mo (~$1,200–$3,600/yr)
ExamplesFountain Life, Human Longevity, CenegenicsLifeforce, Next Health, Healthspan, CoreAge Rx
Core productWhole-body MRI, coronary CT, genomics, in-person MDRecurring labs + prescribing clinician + retesting + therapies
What it is best atDeep one-time diagnostic pictureLongitudinal treatment and monitoring at an accessible price
Honest catchOver-screening risk; bolt-on unproven therapies"Healthspan" framing; GH red flag; vertical-pharmacy conflicts
Key question: are you buying a diagnostic picture (one-time depth) or an ongoing treatment plan (longitudinal care)? Neither model has been shown to extend human lifespan.

What a concierge clinic actually delivers

Fountain Life, Human Longevity (Health Nucleus), and Cenegenics define this band. The product is diagnostics you genuinely cannot get elsewhere as a consumer: whole-body and brain MRI, coronary CT angiography with AI plaque analysis, whole-genome sequencing, 100+ biomarker panels, and a physician who quarterbacks all of it in person. Fountain Life's flagship runs about $19,500/yr; Human Longevity's concierge tier reaches roughly $19,000/yr; Cenegenics programs land around $14,000–$21,000/yr once you add the assessment and monthly fees.

What you're really paying for: the depth and the imaging. For some people, a scan catches something genuinely important early — and that is the legitimate case for the model.

The honest catch — over-screening: intensive scanning of asymptomatic people is a double-edged sword, and the data are now specific. A 2026 systematic review and meta-analysis of whole-body MRI across more than 9,000 asymptomatic individuals found a confirmed-cancer detection rate of just 1.57%, alongside frequent incidental findings, unstandardized protocols, and no long-term outcome or cost-effectiveness data — concluding the scans "may lead to unnecessary investigations"1. In plain terms: the imaging that anchors the concierge pitch finds real cancer in about 1 in 64 healthy people, while flagging far more ambiguous spots that drive anxiety, follow-up procedures, and cost. That's not a reason to never scan; it's a reason to treat "early detection" marketing with the skepticism the evidence warrants.

The second concierge catch is the bolt-on. Several clinics in this band attach interventions — plasma exchange, EBOO, NAD+, peptides, growth-hormone secretagogues — to the diagnostic core. Treat the imaging and genomics as the real product and the "reverse aging" add-ons as unproven; we trace the evidence gaps in longevity medicine: what's proven vs hyped.

What a membership program actually delivers

Lifeforce, Next Health, Healthspan, and where CoreAge Rx sits define this band. The model is recurring: a structured panel of 40–100 biomarkers, scheduled retesting every few months, a clinician who reviews results and prescribes, and a menu of therapies — hormone optimization, peptides, GLP-1s, NAD+. Lifeforce runs about $149/mo after a $549 diagnostic; Next Health tiers from roughly $99 to $399/mo. The whole thing usually happens over telehealth with mailed lab kits, which is why it costs a fraction of the concierge model.

What you're really paying for: the thing a DTC lab won't give you and a one-time concierge scan can't — a clinician who can actually prescribe, plus a retesting cadence that lets you see whether an intervention moved your numbers. This is the only band built for longitudinal treatment at an accessible price.

The honest catch — the claims and the conflicts: this band leans hardest on the word "healthspan," and much of what it prescribes — NAD+, peptides, rapamycin — has mechanistic plausibility but no completed human longevity RCT. Two specific things to vet. First, vertical-pharmacy conflict: some membership brands dispense through their own pharmacy, meaning the company recommending a therapy also profits from selling it. Second, the growth-hormone red flag: any program marketing GH or GH-secretagogue peptides as anti-aging is ignoring the evidence — a landmark systematic review of growth hormone in healthy older adults found small body-composition changes but no proven functional benefit and significantly more adverse events2. A good membership provider distinguishes proven from plausible and discloses its conflicts; that honesty is exactly what we grade in are longevity clinics worth it?, and it's the heaviest-weighted axis in how we grade longevity providers.

Where the evidence stands across both models

It's worth stating plainly, because the marketing in both bands blurs it: no intervention sold by either a concierge clinic or a membership program has been shown in a completed randomized trial to extend human lifespan. The strongest human outcome data in the entire field belongs to GLP-1 receptor agonists — the SELECT trial showed semaglutide cut major cardiovascular events by about 20% in overweight and obese adults without diabetes3 — and even that proves cardiovascular risk reduction, not slowed aging. The deeper reason both models operate ahead of their proof: the methodology to run true human healthspan trials is only now maturing, so validated aging endpoints barely exist yet4. A concierge clinic and a $149/mo membership are, at bottom, both selling care in a field where the outcome trials haven't read out.

That shared baseline is liberating, because it collapses the decision to something practical: since neither model can promise a longer life, you're choosing between the best diagnostic picture and the best ongoing treatment relationship — not between "more proven" and "less proven."

Which one is for you?

  • Choose concierge if you want the deepest one-time diagnostic picture, money is genuinely no object, and you'll go in clear-eyed about over-screening. Pay for the imaging and genomics; ignore the bolt-on "reverse aging" interventions.
  • Choose membership if you want ongoing, prescribed care with retesting and a clinician you can actually reach — at a price that doesn't require a five-figure budget. This is the band that treats. Vet it for vertical-pharmacy conflict and for honesty about what's proven.
  • Consider both, sequenced, if budget allows: a one-time concierge or DTC diagnostic snapshot for breadth, then a membership program for the longitudinal treatment a scan can't provide. What you should never do is pay concierge prices for membership-grade therapy — the imaging is the only thing the premium reliably buys.

A physician-overseen peptide/NAD+/GLP-1 telehealth membership sits squarely in the membership band's value lane: more clinically active than a DTC lab, more longevity-focused than an influencer TRT brand, and a fraction of concierge pricing — real oversight without the $20k diagnostic tax. For our independently graded shortlist across every band, with the conflicts and unproven claims flagged, see our longevity provider rankings. For a full breakdown of what every tier costs — from ~$200/yr lab memberships to $20k+ concierge programs — see how much does a longevity clinic cost?.

Frequently asked questions

What's the difference between a concierge longevity clinic and a membership program?

A concierge clinic ($8k–$25k/yr — Fountain Life, Human Longevity, Cenegenics) sells diagnostics: whole-body MRI, coronary CT, genomics, and a physician to interpret them, usually in person. A membership program ($99–$300/mo — Lifeforce, Next Health, CoreAge Rx) sells ongoing treatment: recurring labs, a prescribing clinician, scheduled retesting, and therapies like peptides, hormones, or GLP-1s, mostly over telehealth. The clinic buys you a one-time picture; the membership buys you an ongoing plan.

Is a $20,000 concierge longevity clinic worth it over a $149/month membership?

Only for the diagnostics. The concierge price buys imaging and genomics you can't get from a telehealth membership. But the intensive screening of healthy people carries real over-diagnosis risk — a 2026 meta-analysis of whole-body MRI in over 9,000 asymptomatic adults found just a 1.57% cancer-detection rate alongside frequent incidental findings that may trigger unnecessary investigations — and the interventions clinics bolt on often have no human outcome data. You should never pay concierge prices for therapies a membership delivers more cheaply.

Do membership longevity programs actually prescribe treatment?

Yes — that's the defining feature of the band. Unlike DTC lab memberships that test and hand you off, a membership program assigns a clinician who reviews your labs, prescribes therapies (hormones, peptides, GLP-1s, NAD+), and retests on a schedule so you can see whether an intervention moved your numbers. The honest caveat: vet for vertical-pharmacy conflicts and for honesty about which therapies have human evidence.

Has either model been proven to extend lifespan?

No. Nothing sold by a concierge clinic or a membership program has been shown in a completed randomized trial to extend human lifespan. The strongest human outcome data belongs to GLP-1 drugs (the SELECT trial showed semaglutide cut cardiovascular events about 20%), and even that proves cardiovascular risk reduction, not slowed aging. Both models operate ahead of the evidence, because validated human healthspan trials are only now maturing.

Should I use a concierge clinic or a membership program first?

If budget allows, a one-time diagnostic snapshot (concierge or a cheaper DTC lab panel) for breadth, then a membership program for the longitudinal treatment a single scan can't provide, is the most useful real-world sequence. If you have to pick one, choose based on what you need: the deepest picture (concierge) or ongoing prescribed care at an accessible price (membership).

References

  1. Martins da Fonseca J, Trennepohl T, Pinheiro LG, et al. (2026). Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis. European Radiology. https://doi.org/10.1007/s00330-025-11976-5
  2. Liu H, Bravata DM, Olkin I, et al. (2007). Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-146-2-200701160-00005
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2307563
  4. Justice JN, Niedernhofer L, Robbins PD, et al. (2018). Development of Clinical Trials to Extend Healthy Lifespan. Cardiovascular Endocrinology & Metabolism. https://doi.org/10.1097/XCE.0000000000000159

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

More graded reviews